H., Dhurandhar, N
Unlike current single (GLP-1) and dual (GLP-1/GIP) agonist compounds like Semaglutide and Tirzepatide , Retatrutide is a triple agonist compound targeting three hormone receptors instead of only one or two: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) GCG (glucagon receptor) According to a landmark clinical trial published in the New England Journal of Medicine , Retatrutide demonstrated significant weight reduction, up to 30%, in participants over a 48-week period, highlighting its potential as a next-generation metabolic peptide
Meal and beta-alanine coingestion enhances muscle carnosine loading
Pharmacol Ther 120:317332 Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H (2006) Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile
A.StaffordB